Full metadata record
DC FieldValueLanguage
dc.creatorBendandi, M. (Maurizio)
dc.date.accessioned2011-11-28T09:10:38Z-
dc.date.available2011-11-28T09:10:38Z-
dc.date.issued2001-
dc.identifier.citationBendandi M. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma. Expert Rev Anticancer Ther 2001 Jun;1(1):65-72.es_ES
dc.identifier.issn1744-8328-
dc.identifier.urihttp://hdl.handle.net/10171/19952-
dc.description.abstractAbstract Cancer vaccines are currently conceived as therapeutic tools, in contrast to the prophylactic vaccines that have resolved the problem of a number of infectious diseases. Among the former, anti-idiotype vaccines for human follicular lymphoma have begun to produce tangible clinical results. Just 10 years ago it was not even known whether patients could be immunized against their own tumor antigens and now as many as two independent Phase III clinical trials based on this finding are underway. The rapidity of this development encourages the hope that active immunotherapy may soon become decisive in oncology. For the time being, many important results have already been achieved: the evidence of vaccine-induced, tumor-specific humoral/cellular responses and the first documented molecular remissions following vaccination.es_ES
dc.language.isoenges_ES
dc.publisherExpert Reviewses_ES
dc.rightsinfo:eu-repo/semantics/closedAccess-
dc.subjectAntibodies, Anti-Idiotypic/therapeutic usees_ES
dc.subjectCancer Vaccines/therapeutic usees_ES
dc.subjectLymphoma, Follicular/therapyes_ES
dc.titleRole of anti-idiotype vaccines in the modern treatment of human follicular lymphomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://www.expert-reviews.com/doi/abs/10.1586/14737140.1.1.65es_ES

Files in This Item:
There are no files associated with this item.


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.